Pfizer announced its 2025 sales and earnings forecast on December 17th, aligning closely with Wall Street's expectations. The company projected adjusted earnings per share between $2.80 and $3, matching the average analyst estimate of $2.88. This forecast comes as Pfizer aims to counter criticism from activist hedge fund Starboard Value, which has challenged the company's strategic direction. Starboard has
Citi maintains a "Hold" rating on Pfizer (PFE) with a target price of $30, following the FDA's decision to place a clinical hold on all infant RSV vaccine trials due to safety concerns with Moderna's candidates. This development is expected to benefit Pfizer's Abrysvo, the only approved maternal RSV vaccine, positioning it as a dominant player in the infant vaccine market. Citi notes, "We believe Pfizer wil
Pfizer, Inc. (PFE) has not been the subject of any significant news today, leaving the stock's movement largely unexplained by recent events. However, discussions on Reddit provide some insight into investor sentiment and strategies involving Pfizer. One user on r/WallStreetBetsELITE shared their decision to sell Pfizer shares, citing underperformance as the primary reason for reallocating funds to Google.
Pfizer, Inc. (PFE) saw its stock decline by 2.03% on December 10, 2024, closing at $25.57, down from the previous close of $26.10. The stock opened at its previous close but quickly dipped to a low of $25.51, reflecting investor reactions to recent developments. The decline was primarily driven by the release of preliminary data from a Phase 1b study of vepdegestrant, a drug developed in collaboration with
Pfizer's stock is experiencing a decline today, partly due to the market's reaction to the preliminary data from a Phase 1b study involving vepdegestrant, a drug developed in collaboration with Arvinas. The data, released on December 10, 2024, showed that while the combination of vepdegestrant and abemaciclib demonstrated a clinical benefit rate of 62.5% in patients with advanced breast cancer, the results
Pfizer's stock is experiencing a decline today, primarily influenced by a recent analyst action. Bank of America reinstated its coverage of Pfizer with a "neutral" rating and set a price target of $29.00 per share. This rating, announced early on December 10th, reflects a cautious stance on the stock, which may have contributed to the downward pressure. Additionally, the broader analyst sentiment towards Pf
Pfizer, Inc. (PFE) has been a topic of discussion on Reddit, particularly regarding its RSV vaccine, ABRYSVO, which has been approved by the FDA for high-risk adults under 60. This approval is significant as it expands the vaccine's availability beyond the previously eligible groups, potentially increasing its market reach. However, some Reddit users have noted that pharmacies are still primarily vaccinatin
Pfizer, Inc. (PFE) has not been the subject of any significant news today, leaving the stock's movement largely unexplained by recent events. However, discussions on Reddit have touched on broader themes related to the company, particularly in the context of vaccine safety and public perception. One user sarcastically remarked, "Doesn’t he realize that they are all safe and effective? That’s all the proof a
Pfizer, Inc. (PFE) is currently under scrutiny on Reddit forums, with discussions focusing on potential layoffs and organizational restructuring expected in the first quarter of the upcoming year. Users on r/biotech have expressed skepticism about the company's annual cycle of layoffs, with one user humorously noting, "Pfizer is the only pharma I have seen with layoff merch. Get your 'I've been Pfizered' t-
Pfizer (PFE) saw its stock rise by 1.86% on December 5, 2024, closing at $25.70, up from the previous day's close of $25.23. The stock opened at $25.23 and reached a high of $25.79 during the trading session, with a volume of 37,070,428 shares, slightly below its average. The uptick in Pfizer's stock can be attributed to several factors, including State Street Corp's recent increase in its stake by 1.2% dur
Pfizer's stock is experiencing an uptick today, likely influenced by a combination of factors. Notably, State Street Corp has increased its stake in Pfizer by 1.2% during the third quarter, as disclosed in their recent SEC filing. This move, along with other institutional investors modifying their holdings, suggests a growing confidence in Pfizer's potential. Additionally, Pfizer's strategic pivot towards t
Pfizer, Inc. (PFE) has been highlighted in recent Reddit discussions as an undervalued stock within the S&P-500, NASDAQ-100, and DOW-30. Despite being categorized as undervalued, some Reddit users express skepticism about Pfizer's future prospects, citing its substantial $67 billion debt and perceived lackluster management. One user commented, "I'd be a little scared of investing in Pfizer with conspiracy t
Pfizer, Inc. (PFE) has been a topic of discussion on Reddit forums, particularly in the context of its status as a dividend stock. In a thread about good dividend stocks, users mentioned Pfizer alongside other companies like Devon Energy and Amgen, highlighting its appeal to dividend investors. One user suggested Pfizer as a potential investment for those interested in dividend growth, noting its reputation
Reddit discussions surrounding Pfizer, Inc. (PFE) have been varied, with some investors expressing optimism about the company's growth potential and dividend yield. One user on r/ValueInvesting mentioned reallocating investments from AT&T to Pfizer, citing the latter's potential for growth and attractive dividend. Another discussion on r/StockTradingIdeas highlighted technical trading signals, with users aw
Pfizer's stock is experiencing a slight decline of 0.04% to $26.16, with no specific news reported today to explain the movement. The stock's price action remains relatively stable, reflecting a lack of significant market-moving events.
On Reddit, discussions about Pfizer are varied, with some users expressing concerns over the company's financial health. In a thread on r/dividends, one user mentioned, "I
Pfizer Inc. (PFE) saw its stock rise by 2.03% on November 25, 2024, closing at $26.17, up from the previous close of $25.65. The stock opened at $25.75 and reached a high of $26.45 during the day, with a significant trading volume of 57,368,808 shares, which is 154.36% of its average daily volume. The upward movement was largely driven by increased institutional interest, as several investment firms, includ
Pfizer Inc. (PFE) shares are up 2.07% to $26.18 as of 3:58 pm on Monday, rising from the previous close of $25.65. The stock's upward movement comes amid a significant increase in institutional investment, as Qsemble Capital Management LP boosted its stake in Pfizer by 178.7% during the third quarter, now holding 185,882 shares valued at $5,379,000. This increase in holdings reflects growing confidence in P
Pfizer Inc. (PFE) shares are up 3.04% to $26.43 as of 9:47 am on Monday, rising from the previous close of $25.65 on November 22nd. The stock's upward movement comes amid increased interest from institutional investors, as evidenced by Daiwa Securities Group Inc. boosting its stake in Pfizer by 25.9% during the third quarter, now holding 804,522 shares valued at $23,283,000. Additionally, Larson Financial G
Pfizer Inc. (PFE) saw its stock rise by 2.07% to close at $25.65 on November 22, 2024, following the announcement of a strategic collaboration with Zai Lab to commercialize XACDURO, a new antibacterial drug, in mainland China. This partnership, which grants Pfizer exclusive rights to commercialize the drug, is expected to enhance patient access to XACDURO, a treatment for carbapenem-resistant Acinetobacter
Pfizer (PFE) shares are up 2.01% to $25.64 as of 11:17 am on Friday, rising from the previous close of $25.13. The stock's upward movement today is primarily driven by the announcement of a strategic collaboration with Zai Lab to commercialize XACDURO, a new antibacterial drug, in mainland China. This partnership, which grants Pfizer exclusive rights to commercialize the drug, aims to leverage Pfizer's comm